APOE genotypes have well-established risk-modifying properties in Alzheimer’s disease (AD) and appear to be implicated in the pathology of aS-pathies, as well [4,5,6,7]. This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.